8-KEarnings & ResultsExhibits & Filings

GILEAD SCIENCES, INC. 8-K Report, Financial Results (Oct 18, 2005)

Filed October 18, 2005For Securities:GILD

Summary

Gilead Sciences, Inc. (GILD) filed a Form 8-K on October 18, 2005, to announce its third-quarter 2005 earnings and financial condition. The report primarily directs investors to a press release (Exhibit 99.1) detailing these results. Importantly, the company highlighted that for the third quarters of 2005 and 2004, there were no non-GAAP financial adjustments, meaning their reported results reflect core operations without unusual, infrequent, or significant transactions for those periods. The only noted non-GAAP adjustment mentioned was for the first quarter of 2004, related to a fair value gain on Eyetech Pharmaceuticals warrants upon its IPO, which the company excluded to provide clearer insight into its core business trends.

Key Highlights

  • 1Gilead Sciences announced its third-quarter 2005 financial results via an 8-K filing on October 18, 2005.
  • 2The filing includes a press release (Exhibit 99.1) with detailed quarterly earnings information.
  • 3For Q3 2005 and Q3 2004, Gilead reported no non-GAAP financial adjustments, indicating clean operational results for these periods.
  • 4The company uses non-GAAP measures to provide insights into comparative operating performance and core business trends.
  • 5A specific non-GAAP adjustment from Q1 2004, related to Eyetech Pharmaceuticals warrants, was highlighted as being excluded from core business analysis.
  • 6The filing is primarily an informational update, directing investors to the accompanying press release for financial specifics.

Frequently Asked Questions

The primary purpose of this 8-K filing is to report Gilead Sciences, Inc.'s financial results for the third quarter ended September 30, 2005, and to provide investors with access to the earnings press release containing these details.

According to the filing, there were no non-GAAP financial adjustments for the third quarter of 2005. This suggests that the reported earnings reflect the company's core operating performance without significant unusual or infrequent transactions for that period.

The filing mentions a specific non-GAAP adjustment made in Q1 2004, which excluded a $20.6 million fair value gain on Eyetech Pharmaceuticals warrants upon its IPO. Gilead uses non-GAAP measures to exclude transactions that management deems unusual, infrequent, or large, in order to provide investors with a clearer view of the company's core business performance and trends.

The detailed financial results for the third quarter ended September 30, 2005, are available in the press release issued by Gilead Sciences on October 18, 2005, which is filed as Exhibit 99.1 to this Form 8-K.